Evidence map›Paper›PMID 37216304›Full record

ArticlePathologica2023

POLE exonuclease domain mutations in endometrial carcinoma: a case report.

Maria Paola Pasciuto, Lara Felicioni, Claudia Zampacorta, Benedetta Ferro, Pietro Di Marino, Francesca Chiara Primavera, Alessandro Lucidi, Rebecca Rossetti, Mattia Barbareschi, Antonio Marchetti and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Maria Paola PasciutoCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Lara FelicioniDiagnostic Molecular Pathology, Unit of Anatomic Pathology, SS Annunziata Hospital, Chieti, Italy.
Claudia ZampacortaCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Benedetta FerroCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Pietro Di MarinoClinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy.
Francesca Chiara PrimaveraClinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy.
Alessandro LucidiDepartment of Obstetrics and Gynecology University of Chieti, Italy.
Rebecca RossettiCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Mattia BarbareschiS. Chiara Hospital, University of Trento, Italy.
Antonio MarchettiCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Fiamma ButtittaCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Emanuela D'AngeloCenter for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
University of Chieti-Pescara · ITOspedale SS. Annunziata · ITOspedale Santa Chiara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma (EC) harboring POLE exonuclease domain mutations occurs in 5-15% of ECs and frequently affects young women with low body mass index (BMI). It presents at early stage as high grade endometrioid histotype with intense tumor infiltrating lymphocytes and has good clinical outcomes and favorable prognosis. In this article we report the case of a 32-year-old woman with endometriod EC (EEC) exhibiting a "ultramutated" molecular profile and an excellent prognosis despite tumor size and grading. Herein, to highlight the importance of defining POLE status in ECs for both clinical and therapeutic implications for patients.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsAdultExonucleasesFemaleHumansMutationPoly-ADP-Ribose Binding ProteinsPrognosisExonucleasesPoly-ADP-Ribose Binding Proteinsendometrial carcinomaPOLEultramutated phenotype

Identifiers

PMID37216304
PMCPMC10462992
OpenAlexW4377237670

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.